EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants

Mohammad Ghasemi, Ji Yun Kim, Lisa Seitz, Lixia Jin, Paul G Foster, Kai H Liao, Tzuling Cheng, Elaine Paterson, Maria Velinova, Nicole Rivera Rosario, Reza Khosravan, Balaji Agoram

British Journal of Clinical Pharmacology · 2025-12 · 91 (12) · 3366-3377

DOI: 10.1002/bcp.70169 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 27.07.2025. Verfasst von Mohammad Ghasemi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Arcus Biosciences, Hayward, California, USA. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Arcus Biosciences, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Casdatifan is an orally bioavailable small‐molecule hypoxia‐inducible factor‐2α (HIF‐2α) inhibitor currently in development for treating patients with clear cell renal cell carcinomas. The aim of this study was to characterize the pharmacokinetics (PK), pharmacodynamics and safety of casdatifan in healthy participants.

Methods

This first‐in‐human study (NCT05117554) investigating casdatifan in 70 healthy participants consisted of 3 parts: a double‐blind, randomized, placebo‐controlled single ascending dose (3–100 mg) part; a multiple ascending dose (15–50 mg once daily) part; and an open‐label, fixed sequence, 2‐period, drug–drug interaction part to evaluate the effect of multiple doses of casdatifan on the single‐dose PK of midazolam.

Results

In healthy participants, casdatifan plasma exposure increased dose proportionally over a single dose of 3–100 mg and multiple daily doses of 15–50 mg. The mean half‐life of casdatifan was approximately 24 h, and PK parameters did not change over time. Dose‐ and concentration‐dependent reduction, ranging from 41 to 85%, in erythropoietin (a pharmacodynamic biomarker for peripheral, nontumour, HIF‐2α inhibition) was observed after single and multiple doses, consistent with HIF‐2α pathway inhibition. Results from the midazolam drug–drug interaction part indicated that casdatifan was a weak CYP3A4 inducer at the tested dose. Urine PK data showed that approximately 30% of the overall casdatifan clearance appears to be via renal clearance.

Conclusions

Casdatifan, after single and multiple dosing in healthy participants, was safe and tolerable. Linear PK was associated with a mean maximum erythropoietin reduction of 85% following a single dose and multiple doses of casdatifan, demonstrating a promising exposure–biological activity profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basic Helix-Loop-Helix ProteinsHumansMaleDouble-Blind MethodAdultFemaleDrug InteractionsHealthy VolunteersYoung AdultMiddle AgedMidazolamHalf-LifeDose-Response Relationship, DrugAdministration, OralEndothelial PAS Domain-Containing Protein 1

Stichwörter der Autor:innen

erythropoietinhypoxia‐inducible factor‐2α inhibitoroncologypharmacodynamicspharmacokinetics

Substanzen

Basic Helix-Loop-Helix ProteinsMidazolamEndothelial PAS Domain-Containing Protein 1

Autor:innen und Institutionen

  • Arcus Biosciences, Hayward, California, USA.
  • ICON Early Clinical & Bioanalytical Solutions, Groningen, Groningen, Netherlands.

Förderung

  • Arcus Biosciences, Inc.

Zitieren

APA

Ghasemi, M., Kim, J. Y., Seitz, L., Jin, L., Foster, P. G., Liao, K. H., Cheng, T., Paterson, E., Velinova, M., Rosario, N. R., Khosravan, R., & Agoram, B. (2025). Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants. British Journal of Clinical Pharmacology, 91(12), 3366-3377. https://doi.org/10.1002/bcp.70169

Vancouver

Ghasemi M, Kim JY, Seitz L, Jin L, Foster PG, Liao KH, et al. Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants. British Journal of Clinical Pharmacology. 2025;91(12):3366-3377. doi:10.1002/bcp.70169

BibTeX
@article{Ghasemi2025,
  author = {Ghasemi, Mohammad and Kim, Ji Yun and Seitz, Lisa and Jin, Lixia and Foster, Paul G and Liao, Kai H and Cheng, Tzuling and Paterson, Elaine and Velinova, Maria and Rosario, Nicole Rivera and Khosravan, Reza and Agoram, Balaji},
  title = {Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {12},
  pages = {3366--3377},
  doi = {10.1002/bcp.70169}
}
Kostenlos starten →